AVROBIO INC's ticker is AVRO and the CUSIP is 05455M100. A total of 55 filers reported holding AVROBIO INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $798 | +49.4% | 518,467 | -7.8% | 0.00% | 0.0% |
| Q2 2023 | $534 | -6.8% | 562,567 | -1.9% | 0.00% | 0.0% |
| Q1 2023 | $573 | -6.8% | 573,367 | -33.5% | 0.00% | 0.0% |
| Q4 2022 | $615 | -99.9% | 862,267 | -29.4% | 0.00% | 0.0% |
| Q3 2022 | $785,000 | -45.1% | 1,222,141 | -21.4% | 0.00% | -50.0% |
| Q2 2022 | $1,431,000 | +22.5% | 1,555,800 | +75.8% | 0.00% | +100.0% |
| Q1 2022 | $1,168,000 | -5.5% | 885,100 | +175.7% | 0.00% | -50.0% |
| Q4 2021 | $1,236,000 | -45.3% | 321,000 | -20.8% | 0.00% | -33.3% |
| Q3 2021 | $2,260,000 | +185.7% | 405,100 | +355.2% | 0.00% | +200.0% |
| Q2 2021 | $791,000 | +39.8% | 89,000 | +119.2% | 0.00% | 0.0% |
| Q4 2020 | $566,000 | +184.4% | 40,600 | +165.4% | 0.00% | – |
| Q3 2020 | $199,000 | -68.8% | 15,300 | -58.1% | 0.00% | -100.0% |
| Q2 2020 | $637,000 | +145.9% | 36,530 | +129.7% | 0.00% | – |
| Q2 2019 | $259,000 | – | 15,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 4,520,863 | $5,968,000 | 0.76% |
| Aisling Capital Management LP | 1,009,779 | $1,333,000 | 0.72% |
| MPM BioImpact LLC | 647,918 | $855,000 | 0.23% |
| GMT CAPITAL CORP | 2,594,914 | $3,425,000 | 0.22% |
| New Leaf Venture Partners, L.L.C. | 315,550 | $417,000 | 0.21% |
| GSA CAPITAL PARTNERS LLP | 338,422 | $447,000 | 0.06% |
| Penn Mutual Asset Management, LLC | 37,306 | $49,000 | 0.06% |
| Eversept Partners, LP | 295,369 | $389,887 | 0.03% |
| XTX Topco Ltd | 23,289 | $31,000 | 0.01% |
| Colonial River Wealth Management, LLC | 17,636 | $23,000 | 0.01% |